Roche Pharmaceutical Development and Sales Overview

R&D focus area Alzheimer's disease Clinical results for gantenerumab and blood-based biomarkers to be presented at CTAD Roche CTAD Clinical Trials on Alzheimer's Disease گولا Pharmaceuticals gantenerumab FDA BTD • Nearly two decades of scientific investigation with nearly 7000 patient years on treatment GRADUATE I/II: Patients with early AD (FDA BTD) SKYLINE: Patients at risk of, or at the earliest stages of AD Brain shuttle gantenerumab Improve transport of gantenerumab across the blood brain barrier Promising Ph I PK data Platform technology: Ph I trial in MS with a CD20 Anti-tau mABs Different MoA, targeting tau protein tangles instead of AB plaques • Two assets (semorinemab & bepranemab) in Ph II trials Roche Diagnostics Blood-based biomarker Elecsys Amyloid Plasma Panel (FDA BDD) A minimally invasive test to help pre-select patients for confirmatory testing Runs on serum work area platforms CSF-based biomarker Elecsys Aẞ and pTau CSF Confirmatory test equivalent to PET scan Runs on serum work area platforms Multiple Real World Data (RWD) studies* *Topics include natural history, predictors of progression in early AD, QoL across the AD continuum and more; Latest RWD study: Delphi study CONCORD-AD 2.0, connecting cohorts to diminish AD AD=Alzheimer's disease; PK-pharmacokinetics; MS=multiple sclerosis; AB-amyloid beta; BDD-breakthrough device designation; CSF-Cerebrospinal fluid; QoL-quality of life FDA BDD 14

View entire presentation